Esophagus to Small Intestine

Lancet Gastroenterol Hepatol. 2025;10(12):1065-1074

van de Pavert YL, Kastelijn JB, Besselink MG, Booij DC, Boonstra JJ, Boot J, Bruno MJ, Busch OR, Daams F, Derksen WJM, Fockens P, Groot Koerkamp B, Hagendoorn J, van Hooft JE, Inderson A, Lammers WJ, Lips DJ, Mieog JSD, Molenaar IQ, Veenhof AAFA, Venneman NG, Verdonk RC, Voermans RP, van Wanrooij RLJ, Welsing PMJ, de Wijkerslooth TR, Moons LMG, van Santvoort HC, Vleggaar FP; Dutch Pancreatic Cancer Group

Endoscopic versus surgical gastroenterostomy for palliation of malignant gastric outlet obstruction (ENDURO): A randomised controlled trial


Background: In patients with malignant gastric outlet obstruction, endoscopic ultrasonography-guided gastroenterostomy might be superior to surgical gastroenterostomy, but randomised trials are scarce. The trial aimed to assess time to resumption of oral intake and the rate of persistent or recurrent obstructive symptoms requiring re-intervention following endoscopic ultrasonography-guided gastroenterostomy compared with surgical gastroenterostomy.
Methods: ENDURO was a multicentre, randomised controlled trial conducted at 12 Dutch academic and teaching hospitals. Hospitals with experience in at least 20 LAMS placements of any indication, at least ten endoscopic gastroenterostomies, and approved competence were eligible to perform endoscopic gastroenterostomy independently within the trial. Adults aged 18 years and older with symptomatic, malignant gastric outlet obstruction in a palliative setting were randomly assigned (1:1) to endoscopic or surgical gastroenterostomy. Randomisation was performed with an electronic data capture system using randomly generated permuted blocks of 2 and 4 and stratified by WHO performance status (0–1 and 2–3). The first coprimary outcome was time to resumption of solid oral intake (Gastric Outlet Obstruction Scoring System score ≥ 2). The second coprimary outcome was non-inferiority for persistent or recurrent obstructive symptoms requiring re-intervention. The predefined non-inferiority margin of the risk difference was 20%. All outcomes were analysed in all randomly assigned participants.
Findings: Between February 18, 2022, and February 26, 2024, 250 patients were screened, 98 of whom were randomly assigned to endoscopic gastroenterostomy (n = 48) or surgical gastroenterostomy (n = 50). 43 (44%) patients were female and 55 (56%) were male. Endoscopic gastroenterostomy had a shorter time to solid oral intake than surgical gastroenterostomy (median 1 day [IQR, 1–3] vs. 3 days [1–6], hazard ratio = 2.21 [95% CI: 1.43–3.42]; p = 0.0003). Endoscopic gastroenterostomy was non-inferior to surgical gastroenterostomy for persistent or recurrent obstructive symptoms requiring re-intervention (5 [10%] vs. 6 [12%], risk difference 1.6% [upper limit of 90% CI: 8.9]). Overall adverse events were reported in 28 (58%) patients in the endoscopic gastroenterostomy group and 32 (64%) in the surgical gastroenterostomy group (relative risk = 0.91 [95% CI: 0.66–1.25]). One fatal event occurred in the endoscopic gastroenterostomy group and three fatal events occurred in the surgical gastroenterostomy group.

Interpretation: In patients with malignant gastric outlet obstruction, palliative treatment with endoscopic gastroenterostomy was superior to surgical gastroenterostomy for time to resumption of solid oral intake and was non-inferior for the rate of persistent or recurrent obstructive symptoms requiring re-intervention. Based on these results, endoscopic gastroenterostomy should be the preferred palliative treatment for patients with malignant gastric outlet obstruction.

F.P. Vleggaar, Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands, e-mail: f.vleggaar@umcutrecht.nl

DOI:  10.1016/s2468-1253(25)00209-2

expert opinion

PD Dr. Armin Küllmer
Head of Endoscopy, University Medical Center Freiburg, Department of Internal Medicine II, Hugstetter Str. 55, 79106 Freiburg, Germany

Endoscopic gastroenterostomy: On the way to becoming the standard for malignant gastric outlet obstruction

Malignant gastric outlet obstruction is a severe complication of oncological diseases that markedly impairs patients’ quality of life. In addition to the established standard of surgically created gastroenterostomy, obstruction may be treated endoscopically using duodenal stents, as well as endoscopic ultrasound-guided gastroenterostomy (EUS-GE), a procedure used with increasing popularity in recent years. A high-impact study published in 2025 (Teoh et al., doi: 10.1016/S2468-1253(25)00136-0) demonstrated the superiority of EUS-GE over endoscopic duodenal stenting. The 2 studies discussed below now address the highly relevant question of how EUS-GE compares with surgically created gastroenterostomy in patients with malignant gastric outlet obstruction.
Both randomized controlled trials—the ENDURO trial conducted in the Netherlands and the GOOSE trial conducted predominantly in the United States with participation from India and Germany—had a similar study design. The evaluated end points focused on clinically relevant outcomes, namely time to resumption of oral intake, the need for reintervention, and occurrence of complications. In simplified terms, the key question can be phrased as follows: does EUS-GE effectively relieve symptoms, and is this effect durable.
The answer is clearly affirmative. In both studies, EUS-GE showed advantages with regard to the aforementioned end points, with the ENDURO trial designed as a non-inferiority study. These findings now confirm, with substantially higher-quality evidence, the results of previous retrospective analyses.
The rapid resumption of oral intake after successful EUS-GE and the short length of hospital stay are well-known clinical observations and can be readily explained by the less invasive nature of the procedure. EUS-GE does not require pneumoperitoneum or suturing, and while a surgical anastomosis must be created at its final diameter, EUS-GE requires only a small, transmural opening—approximately 3.5 mm—between the stomach and small intestine for stent deployment. For most patients, the modest time advantage in resuming oral intake compared with surgical gastroenterostomy is unlikely to be clinically decisive; similarly, the initiation of systemic therapy did not differ significantly between treatment groups.
More surprising is the lower reintervention rate observed over a follow-up period of up to 6 months. In the palliative setting of this patient population, this represents a clinically meaningful time frame. A longer follow-up would likely not have been informative given the high disease-related mortality.
Does this mean that EUS-GE is on its way to becoming the new standard of care? For centers with appropriate expertise, both trials provide strong arguments in favor of selecting an endoscopic approach as first-line therapy and potentially establishing it as the preferred standard. Nevertheless, the procedure remains technically demanding, and management of complications can be complex. Careful patient selection and substantial expertise in interventional endoscopic ultrasound are therefore essential to ensure safe and successful implementation.

Back to overview

this could be of interest:

More articles on the topic